A Phase I/II Study of Ipilimumab Immunotherapy after Stem Cell Transplantation in People with Recurrent or Persistent Multiple Myeloma

Share
Print

Full Title

A Phase I/II Trial of Ipilimumab after CD34-Selected Allogeneic Stem Cell Transplantation for Patients with Relapsed/Refractory Multiple Myeloma

Purpose

Allogenic stem cell transplantation, the receipt of stem cells from a matched donor, is used to treat some patients with multiple myeloma that has continued to grow or came back despite other treatments. In this study, researchers want to see if adding the immunotherapy drug ipilimumab after the stem cell transplant can reduce the chance of the cancer from coming back. They believe that ipilimumab may help boost the power of the immune system to fight the cancer. Ipilimumab is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that came back or has continued to grow despite at least two prior regimens of therapy.
  • Patients must be candidates for allogeneic stem cell transplantation and have a fully matched stem cell donor.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients who are at least age 21 and under age 73.

For more information and to inquire about eligibility for this study, please contact Dr. Gunjan Shah at 646-608-3734.

Protocol

20-329

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators